Key Highlights
- Centene shares fell 7.0% to $67.45 on November 18.
- CMS proposed extrapolating Medicare Advantage audit findings to broader insurer payments.
- Comments on the proposal are open until January 19, 2027.
- Third-quarter EPS of $0.58 beat the $0.09 consensus.
The move
Why did Centene Corporation (NYSE:CNC) shares plunge? The stock fell 7.0% to $67.45 on November 18, according to market data, as managed care stocks extended a sell-off triggered by a proposed federal rule on Medicare Advantage audits. The Centers for Medicare & Medicaid Services proposed a rule, nicknamed CRUSH in market commentary, that would extrapolate findings from Medicare Advantage risk-adjustment audits to broader payments, potentially increasing the amounts insurers must repay for unsupported diagnosis codes.
Comments on the proposal are open until January 19, 2027. The rule was proposed early in the week, and insurers fell for a second straight day on Wednesday. Humana (NYSE:HUM) dropped about 13%, UnitedHealth (NYSE:UNH) about 10%, Elevance (NYSE:ELV) about 7.6% and CVS Health (NYSE:CVS) about 5.2%, according to market data. UnitedHealth was the biggest drag on the Dow, which fell 1.11%.
Centene's decline was notable because the stock had been one of 2026's best health-care performers, roughly doubling over the past year from depressed levels, according to market data.
What the company does
Centene, based in St. Louis, is the largest Medicaid managed care company in the US. It also operates one of the biggest Affordable Care Act Marketplace businesses, Medicare Advantage and Medicare Part D plans under the Wellcare brand, and other government programs, including military health services. In 2026, Wellcare offers Medicare Advantage plans in 32 states and prescription drug plans in all 50 states, according to the company's quarterly filing.
Revenue per employee
Centene is on a list of US companies with the highest Revenue per employee, according to market data. Its annual revenue guidance is in the range of about $196.5 billion to $200.5 billion, according to a summary of its latest results. Health insurers collect premiums from governments and members and pay out most of that money for medical care delivered by hospitals and doctors outside the company, so revenue per employee is extremely high even though profit margins are thin.
Medicare Advantage exposure
Medicaid remains Centene's largest business, but Medicare is significant. Third-quarter Medicare revenue, which includes Medicare Advantage, Part D and supplement plans, was about $11.3 billion, up 20% year over year, according to the company's 8-K. The Medicare segment's health benefits ratio improved on outperformance in both Medicare Advantage and Part D. Audit extrapolation could expose insurers to larger repayment obligations and add uncertainty to future margins. Centene's filings also note that CMS has been expanding the number of Medicare Advantage contracts it audits each year.
Recent results and valuation
In its third-quarter report, Centene's EPS of $0.58 beat the $0.09 consensus on revenue of about $50.6 billion, according to market data, and the company raised its revenue guidance. Earlier in the year, Centene's Marketplace Business faced severe pressure as enhanced premium subsidies expired and membership fell, but corrective pricing actions for 2026 have improved results. After Wednesday's drop, the stock trades within a 52-week range of $31.63 to $78.08. Market data classifies it as modestly undervalued relative to an estimate of intrinsic value. Centene does not pay a dividend.
Sector context
Managed care has been one of the most volatile sectors in the US market over the past two years, buffeted by elevated medical cost trends, changes to Medicare Advantage payment rates, ACA Subsidy expirations and Medicaid redeterminations. Policy risk has risen further since sweeping Democratic gains in the midterm elections earlier this month. The CMS proposal adds another layer of Regulatory Risk just as the sector had been recovering.
Risks
Key risks include the final form of the audit rule and any retroactive repayment obligations, Medicaid rate adequacy from states, Marketplace membership declines and risk-adjustment transfers, medical cost trends, and ongoing securities litigation and an SEC investigation cited by analysts. Political developments in Washington could also change program funding.
Key numbers at a glance
Close: $67.45 (November 18), down 7.0%. 52-week range: $31.63 to $78.08. One-year change before the drop: roughly a doubling, according to market data. Third-quarter EPS: $0.58 versus $0.09 expected. Third-quarter revenue: about $50.6 billion. Third-quarter Medicare revenue: about $11.3 billion, up 20%. Comment deadline on the CMS audit proposal: January 19, 2027.
How the session unfolded
Health insurers dominated Wednesday's market narrative. UnitedHealth, which carries a heavy weighting in the price-weighted Dow, fell about 10% and drove much of the index's 561-point decline, according to market data. Humana, the insurer most dependent on Medicare Advantage, dropped about 13%. Hospital operators were also hit, with Ardent Health (NYSE:ARDT) down about 19%, according to market data. The broader S&P 500 fell 0.23%, while the Nasdaq rose on a rebound in chip stocks. Fed minutes released in the afternoon added to the risk-off mood outside technology.
Why audit extrapolation matters
Medicare Advantage plans are paid more for enrolling sicker members, based on diagnosis codes submitted for each patient. CMS audits samples of those records to check whether the codes are supported. Extrapolation means applying the error rate found in a sample to a plan's entire contract, which can turn a small number of disputed records into a large repayment. Federal estimates have pointed to billions of dollars in annual overpayments across the industry, and CMS has been expanding its audit programme. A final rule could therefore have a material financial effect on insurers with large Medicare Advantage books.
What to watch next
Watch industry comments and any lobbying response before the January 19, 2027 comment deadline, the 2027 Medicare Advantage rate notice due in early 2027, Medicaid rate updates and Centene's fourth-quarter results, scheduled for February 5, 2027.
Sector Pressure, Not a Company Miss
Centene's drop was a sector-wide reaction to regulatory risk rather than a company-specific miss. Its Medicaid focus makes it somewhat less exposed than Humana or UnitedHealth, but after a strong run, investors were quick to take profits.




_11_19_2026_08_23_11_186799.jpg)

Please wait processing your request...